Bionano Genomics (Bionano Genomics) Total Current Assets : $85.61 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Bionano Genomics's total current assets for the quarter that ended in Mar. 2024 was $85.61 Mil.

Bionano Genomics Total Current Assets Historical Data

The historical data trend for Bionano Genomics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Total Current Assets Chart

Bionano Genomics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

28.26

46.79

272.41

157.30

140.12

Bionano Genomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															142.56	122.58	104.54	140.12	85.61

Bionano Genomics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Bionano Genomics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	101.888	+	9.661	+	22.892	+	5.677
	=	140.12

Bionano Genomics's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	52.766	+	8.313	+	19.587	+	4.945
	=	85.61

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Bionano Genomics (NAS:BNGOW) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Bionano Genomics's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	52.766	-	75.224	+	0.75 * 8.313	+	0.5 * 19.587
=	-6.43

Bionano Genomics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics (Bionano Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGOW) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

BNGO:USA BNGO:Mexico

Address

9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.